A Phase 3 interventional study of Placebo and KBP-5074 in Chronic Kidney Diseases, sponsored by Novo Nordisk A/S. Terminated at 215 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 12th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 11 more countries
Ages 18+
Novo Nordisk A/S · Sites in Korea, Republic of
Ages 19+
Novo Nordisk A/S · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–75
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 666 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 128 across the 18 interventional studies, 1,500 across the 11 observational. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Renal Insufficiency, Chronic by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07808788Novo Nordisk A/SA Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function | 2027-07-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [eGFR {EPI}] ≥15 to ≤44 mL/min/1.73 m\^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and \<180 mm Hg and taking 2 or more antihypertensive medications.
Participants in this study will be recruited, screened, and enrolled at approximately 140 study sites globally.
The study will consist of the following periods:
During, 24-week Double-blind Treatment Period, 24-week Open-label Treatment Period, and at 4-week Randomized Double-blind Withdrawal Period, the background antihypertensive medications change may or may not be allowed.
At Double-blind Treatment Period, eligible participants will be randomly assigned in a 1:1 ratio to KBP-5074 0.25 mg or matching placebo once daily (QD).
At the Randomized Double-blind Withdrawal Period, participants who meet the randomized withdrawal criteria will be randomly assigned in a 1:1 ratio to continue their current KBP-5074 dose at the end of the Open-label Treatment Period or matching placebo QD.
The study design included a pre-planned futility determination by an Independent Data Monitoring Committee (IDMC).
The trial was originally sponsored by KBP Biosciences PTE Ltd, but sponsorship was transferred to Novo Nordisk after the trial was terminated following the futility determination by IDMC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must have uncontrolled hypertension defined as meeting both of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56.
Drug: Placebo
Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56.
Drug: KBP-5074
Participants will orally receive placebo matching to KBP-5074 tablets QD.
Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12
Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated.
Time frame: From baseline to Week 12
Change in Seated Trough Cuff SBP From Week 48 to Week 52
Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated.
Time frame: From Week 48 to Week 52
Change in Seated Trough Cuff SBP From Baseline to Week 24
Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated.
Time frame: From baseline to Week 24
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated.
Time frame: From baseline to Week 12
Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated.
Time frame: From baseline to Week 12
Percentage Changes in UACR From Baseline to Week 12 and Week 24 for Participants With UACR ≥30 mg/g at Baseline
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
Time frame: From baseline to Week 12 and Week 24
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.
Time frame: From baseline to Week 24
Changes in Seated Trough Cuff DBP From Baseline to Week 48
Effect of KBP-5074 on DBP by assessing change in seated trough cuff SBP was evaluated.
Time frame: From baseline to Week 48
Changes in Seated Trough Cuff SBP From Baseline to Week 48
Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP was evaluated.
Time frame: From baseline to Week 48
Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline was evaluated.
Time frame: From baseline to Week 24
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.
Time frame: From baseline to Week 12, Week 24, and Week 48
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.
Time frame: From baseline to Week 12, Week 24, and Week 48
Change in Seated Trough Cuff DBP From Week 48 to Week 52
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.
Time frame: From Week 48 to Week 52
Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
Time frame: Week 48 to Week 52
Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
Time frame: From Week 48 to Week 52
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
The safety and tolerability of KBP-5074 was evaluated. A treatment emergent adverse event (TEAE) was defined as any AE with onset during or after first dose and before 4 weeks after last dose of study drug, or any preexisting AE/condition that worsened during this period. Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease.
Time frame: Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated.
Time frame: From baseline to Week 12, Week 24, and Week 48
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated.
Time frame: From baseline to Week 12, Week 24, and Week 48
Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
Time frame: From Week 48 to Week 52
Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
Time frame: From Week 48 to Week 52
Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
Time frame: From Week 48 to Week 52
Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
Time frame: From Week 48 to Week 52
Study was conducted at 132 sites in 21 countries globally. Data from site 508 was excluded due to reliability concerns. 666 participants were enrolled (in Run-In Period) in the study and 556 participants were randomized in the double-blind period. 497 participants who completed double-blind period moved to open-label period. 243 participants who completed open-label KBP-5074 treatment were randomized to continue KBP-5074 or receive matching placebo in the double-blind withdrawal period.
| Milestone | Double-blind Treatment Period: KBP-5074 | Double-blind Treatment Period: Placebo | Open-label (OL) Treatment Period: KBP-5074 OL | Randomization Double-blind Withdrawal (W) Period: KBP-5074-W | Randomization Double-blind Withdrawal (W) Period: Placebo-W |
|---|---|---|---|---|---|
| Started | 281 | 275 | 0 | 0 | 0 |
| Completed | 251 | 246 | 0 | 0 | 0 |
| Not completed | 30 | 29 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 20 | 20 | 0 | 0 | 0 |
| Withdrew: Noncompliance with the protocol | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Noncompliance with study drug | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 3 | 0 | 0 | 0 |
| Withdrew: Randomized in error | 0 | 2 | 0 | 0 | 0 |
| Milestone | Double-blind Treatment Period: KBP-5074 | Double-blind Treatment Period: Placebo | Open-label (OL) Treatment Period: KBP-5074 OL | Randomization Double-blind Withdrawal (W) Period: KBP-5074-W | Randomization Double-blind Withdrawal (W) Period: Placebo-W |
|---|---|---|---|---|---|
| Started | 0 | 0 | 497 | 0 | 0 |
| Completed | 0 | 0 | 243 | 0 | 0 |
| Not completed | 0 | 0 | 254 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 15 | 0 | 0 |
| Withdrew: Noncompliance with the protocol | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 4 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 210 | 0 | 0 |
| Withdrew: Trial site terminated by sponsor | 0 | 0 | 15 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 6 | 0 | 0 |
| Milestone | Double-blind Treatment Period: KBP-5074 | Double-blind Treatment Period: Placebo | Open-label (OL) Treatment Period: KBP-5074 OL | Randomization Double-blind Withdrawal (W) Period: KBP-5074-W | Randomization Double-blind Withdrawal (W) Period: Placebo-W |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 125 | 118 |
| Completed | 0 | 0 | 0 | 115 | 108 |
| Not completed | 0 | 0 | 0 | 10 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 6 | 8 |
| Withdrew: Trial site terminated by sponsor | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated.
| mm Hg (millimeters of mercury) | KBP-5074 | Placebo |
|---|---|---|
| Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12 | -12.9 ± 18.02 | -12.4 ± 18.73 |
Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated.
| mm Hg | KBP-5074 | Placebo |
|---|---|---|
| Change in Seated Trough Cuff SBP From Week 48 to Week 52 | -0.9 ± 15.45 | 0.9 ± 15.91 |
Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated.
| mm Hg | KBP-5074 | Placebo |
|---|---|---|
| Change in Seated Trough Cuff SBP From Baseline to Week 24 | -15.3 ± 17.76 | -12.8 ± 17.30 |
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated.
| mm Hg | KBP-5074 | Placebo |
|---|---|---|
| Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12 | -6.3 ± 11.74 | -5.6 ± 11.53 |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated.
| mg/g (milligram/gram) | KBP-5074 | Placebo |
|---|---|---|
| Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline | -80.43 (-2848.0 to 1091.3) | -12.65 (-3261.0 to 4467.8) |
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
| Percentage change | KBP-5074 | Placebo |
|---|---|---|
| Week 12 | -22.43 (-98.0 to 342.7) | -9.10 (-99.6 to 3094.4) |
| Week 24 | -34.37 (-98.3 to 407.8) | -12.50 (-99.5 to 2865.0) |
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.
| mm Hg | KBP-5074 | Placebo |
|---|---|---|
| Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24 | -6.3 ± 12.09 | -6.7 ± 12.43 |
Effect of KBP-5074 on DBP by assessing change in seated trough cuff SBP was evaluated.
| mm Hg | KBP-5074 | Placebo |
|---|---|---|
| Changes in Seated Trough Cuff DBP From Baseline to Week 48 | -8.1 ± 11.09 | -10.0 ± 12.00 |
Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP was evaluated.
| mm Hg | KBP-5074 | Placebo |
|---|---|---|
| Changes in Seated Trough Cuff SBP From Baseline to Week 48 | -13.1 ± 16.64 | -17.2 ± 18.23 |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline was evaluated.
| mg/g (milligram/gram) | KBP-5074 | Placebo |
|---|---|---|
| Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline | -140.90 (-4503.7 to 1860.8) | -11.44 (-3256.2 to 4716.8) |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.
| mg/g | KBP-5074 | Placebo |
|---|---|---|
| Week 12 | -252.62 (-2848.0 to 1091.3) | -104.83 (-3261.0 to 4467.8) |
| Week 24 | -350.58 (-4503.7 to 1860.8) | -70.30 (-3256.2 to 4716.8) |
| Week 48 | -285.12 (-2599.1 to 838.5) | -317.71 (-3567.1 to 4518.3) |
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated.
| Percentage change | KBP-5074 | Placebo |
|---|---|---|
| Week 12 | -22.54 (-98.0 to 284.0) | -11.40 (-99.6 to 197.5) |
| Week 24 | -38.74 (-98.3 to 144.2) | -12.57 (-99.5 to 386.4) |
| Week 48 | -40.20 (-99.5 to 196.4) | -47.43 (-99.5 to 1378.4) |
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated.
| mm Hg | KBP-5074-W | Placebo-W |
|---|---|---|
| Change in Seated Trough Cuff DBP From Week 48 to Week 52 | 0.6 ± 9.59 | 0.6 ± 10.98 |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
| mg/g | KBP-5074-W | Placebo-W |
|---|---|---|
| Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline | -17.31 (-523.8 to 5366.4) | 9.38 (-1320.7 to 3905.9) |
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
| Percentage change | KBP-5074-W | Placebo-W |
|---|---|---|
| Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline | -15.16 (-76.0 to 132.0) | 20.23 (-99.5 to 5133.0) |
The safety and tolerability of KBP-5074 was evaluated. A treatment emergent adverse event (TEAE) was defined as any AE with onset during or after first dose and before 4 weeks after last dose of study drug, or any preexisting AE/condition that worsened during this period. Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease.
| Participants | KBP-5074 | Placebo | KBP-5074 OL | KBP-5074-W | Placebo-W |
|---|---|---|---|---|---|
| Any TEAE | 154 | 154 | 286 | 40 | 35 |
| Any TEAE Related to Study Drug | 40 | 18 | 60 | 5 | 7 |
| Any Severe TEAEs | 12 | 16 | 19 | 1 | 1 |
| Any Severe TEAE Related to Study Drug | 2 | 1 | 0 | 0 | 0 |
| Any TEAE With Outcome of Death | 1 | 0 | 2 | 0 | 0 |
| Any Fatal TEAE Related to Study Drug | 0 | 0 | 0 | 0 | 0 |
| Any Serious TEAE (TESAE) | 20 | 30 | 27 | 4 | 1 |
| Any Non-serious TEAE | 151 | 151 | 281 | 39 | 35 |
| Any Serious TEAE Related to Study Drug | 0 | 1 | 0 | 0 | 0 |
| Any TEAE Leading to Discontinuation of Treatment | 12 | 7 | 16 | 2 | 1 |
| Any TEAE Leading to Discontinuation of Study | 9 | 8 | 6 | 0 | 0 |
| Any TEAE Leading to Study Drug Reduced | 0 | 2 | 2 | 1 | 0 |
| Selected TEAEs | 69 | 43 | 131 | 16 | 13 |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated.
| mg/g | KBP-5074 | Placebo |
|---|---|---|
| Week 12 | -10.98 (-180.4 to 503.5) | -5.46 (-248.8 to 1095.4) |
| Week 24 | -16.96 (-208.5 to 516.0) | -7.32 (-214.6 to 1127.2) |
| Week 48 | -23.75 (-248.4 to 1715.6) | -7.05 (-231.0 to 1622.1) |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated.
| Percentage change | KBP-5074 | Placebo |
|---|---|---|
| Week 12 | -22.23 (-91.0 to 342.7) | -6.44 (-89.9 to 3094.4) |
| Week 24 | -27.93 (-91.5 to 407.8) | -12.27 (-92.2 to 2865.0) |
| Week 48 | -27.39 (-95.1 to 1977.5) | -11.39 (-80.2 to 2976.1) |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
| mg/g | KBP-5074-W | Placebo-W |
|---|---|---|
| Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria | -11.76 (-274.8 to 24.2) | 9.07 (-561.4 to 1547.4) |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
| Percentage change | KBP-5074-W | Placebo-W |
|---|---|---|
| Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria | -15.85 (-57.8 to 132.0) | 26.84 (-64.2 to 246.0) |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
| mg/g | KBP-5074-W | Placebo-W |
|---|---|---|
| Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria | -42.15 (-523.8 to 5366.4) | 13.66 (-1320.7 to 3905.9) |
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame.
| Percentage change | KBP-5074-W | Placebo-W |
|---|---|---|
| Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria | -11.98 (-76.0 to 109.7) | 7.64 (-99.5 to 5133.0) |
Collected over Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| KBP-5074 | 2/281 (0.7%) | 20/281 (7.1%) | 39/281 (13.9%) |
| Placebo | 0/273 (0%) | 30/273 (11%) | 16/273 (5.9%) |
| KBP-5074 - OL | 4/469 (0.9%) | 27/469 (5.8%) | 83/469 (17.7%) |
| KBP-5074 - W | 0/99 (0%) | 4/99 (4%) | 13/99 (13.1%) |
| Placebo - W | 0/107 (0%) | 1/107 (0.9%) | 6/107 (5.6%) |
| Event | KBP-5074 | Placebo | KBP-5074 - OL | KBP-5074 - W | Placebo - W |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 3/281 | 7/273 | 4/469 | 0/99 | 0/107 |
| Chronic kidney diseaseRenal and urinary disorders | 5/281 | 4/273 | 1/469 | 0/99 | 0/107 |
| COVID-19Infections and infestations | 0/281 | 4/273 | 0/469 | 0/99 | 0/107 |
| Cerebral infarctionNervous system disorders | 0/281 | 3/273 | 0/469 | 0/99 | 0/107 |
| Acute kidney injuryRenal and urinary disorders | 3/281 | 1/273 | 2/469 | 0/99 | 0/107 |
| HyperkalaemiaMetabolism and nutrition disorders | 3/281 | 1/273 | 0/469 | 0/99 | 0/107 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/281 | 1/273 | 0/469 | 1/99 | 0/107 |
| Cardiac failure acuteCardiac disorders | 0/281 | 0/273 | 1/469 | 1/99 | 0/107 |
| Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/281 | 0/273 | 0/469 | 1/99 | 0/107 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/281 | 0/273 | 0/469 | 1/99 | 0/107 |
| Event | KBP-5074 | Placebo | KBP-5074 - OL | KBP-5074 - W | Placebo - W |
|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 25/281 | 9/273 | 59/469 | 0/99 | 0/107 |
| Glomerular filtration rate decreasedInvestigations | 16/281 | 9/273 | 32/469 | 7/99 | 6/107 |
| AnaemiaBlood and lymphatic system disorders | 0/281 | 0/273 | 0/469 | 6/99 | 6/107 |
The intent to treat (ITT) population was defined as all randomized participants after removal of participants from site 508.
| Age, Continuous(Years) | KBP-5074 | Placebo | Total |
|---|---|---|---|
| Mean | 67.4 ± 10.87 | 67.9 ± 10.85 | 67.6 ± 10.85 |
| Sex: Female, Male(Participants) | KBP-5074 | Placebo | Total |
|---|---|---|---|
| Female | 98 | 116 | 214 |
| Male | 183 | 159 | 342 |
| Race/Ethnicity, Customized(Participants) | KBP-5074 | Placebo | Total |
|---|---|---|---|
| Hispanic/Latino | 41 | 39 | 80 |
| Not Hispanic/Latino | 232 | 231 | 463 |
| Not reported | 6 | 4 | 10 |
| Unknown | 2 | 1 | 3 |
Showing the first 100 of 215 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Jan 2024, 26 months.
Results were first posted in Nov 2026, 2 years 9 months after primary completion. A results delay was requested in Aug 2024.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KBP-5074
Renal Insufficiency, Chronic →